clinical trial · NCT04522167
Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration
Bioeq GmbH·phase3·completed·n = 434
Neovascular Age-related Macular DegenerationFYB203 (Proposed aflibercept biosimilar)Eylea® (Aflibercept)
brief summary
This is a randomized, double-masked, multicenter study to evaluate the efficacy and safety of FYB203 compared to Eylea® in patients with neovascular age related macular degeneration.
started
Jul 21, 2020
primary completion
Jun 23, 2022
completion
May 18, 2023
last updated
Nov 13, 2025
official title
A Phase 3 Randomized, Double-masked, Multicenter Study to Compare the Efficacy and Safety of the Proposed Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol